Search
A The Kids Research Institute Australia spin-off company, Inspiring Holdings Pty Ltd (Inspiring), has been announced as winner of the Wesfarmers Wellbeing Platinum Award in the prestigious WA Innovator of the Year awards for their novel Universal Spacer System – a device which improves the delivery of inhaled dru
Two researchers focused on improving outcomes for children with chronic lung disease and averting suicide contagion and suicide clusters in young people have won prestigious Investigator Grants from the National Health and Medical Research Council.
September marks the three-month milestone of an intensive health promotion campaign in the East Kimberley region, which aims to raise awareness of the dangers of a chronic wet cough in Aboriginal children.
The Kids Easy Breathing Study kickstarts this month, with the aim of finding out how the airway surface is different between infants who develop chronic lung disease after contracting bronchiolitis compared with those who don’t.
One way the Wal-yan Respiratory Research Centre provides the opportunity for consumers and community members to contribute to our research is through participation in one of our eight community reference groups.
Tick bites and tick-related diseases are on the rise. Diagnostic tests that identify well-characterised tick-borne pathogens (TBPs) possess limited capacity to address the causation of symptoms associated with poorly characterised tick-related illnesses, such as debilitating symptom complexes attributed to ticks (DSCATT) in Australia. Identification of local signals in tick-bitten skin that can be detected systemically in blood would have both clinical (diagnostic or prognostic) and research (mechanistic insight) utility, as a blood sample is more readily obtainable than tissue biopsies.
Cough is the most common symptom leading to medical consultation. Chronic cough results in significant health care costs, impairs quality of life, and may indicate the presence of a serious underlying condition. Here, we present a summary of an updated position statement on cough management in the clinical consultation.
Bronchiectasis is a worldwide chronic lung disorder where exacerbations are common. It affects people of all ages, but especially Indigenous populations in high-income nations. Despite being a major contributor to chronic lung disease, there are no licensed therapies for bronchiectasis and there remain relatively few randomised controlled trials (RCTs) conducted in children and adults.
Bronchiectasis, particularly in children, is an increasingly recognised yet neglected chronic lung disorder affecting individuals in both low-to-middle and high-income countries. It has a high disease burden and there is substantial inequity within and between settings. Furthermore, compared with other chronic lung diseases, considerably fewer resources are available for children with bronchiectasis.
Sputum induction is widely used in clinical settings for collection of biological samples from the lower airways. However, in recent years sputum induction has been associated with serious adverse events and even death. This position statement was commissioned by the Thoracic Society of Australia and New Zealand to address major adverse events of two deaths associated with sputum induction that have occurred in Australia in 2021, and outlines best practice for the safe use of sputum induction.